Answers are grounded in this paper and cite their sources.
Background Gabapentinoids are used in multimodal analgesia, but their association with persistent opioid use after lumbar fusion remains uncertain. This systematic review and meta-analysis compared adults exposed to gabapentin or pregabalin with unexposed patients. The primary outcome was persistent opioid use or prescription. Inpatient opioid consumption, postoperative pain, and disability were assessed as secondary outcomes. Methods The PubMed, Embase, and the Cochrane Library databases were searched through 30 August 2026. Comparative studies of adults undergoing spinal fusion were eligible if they evaluated gabapentinoid exposure vs no exposure under usual care or a comparable opioid-based regimen. Two reviewers independently selected studies, extracted data, and assessed risk of bias using ROBINS-I. Cohorts with a high probability of overlap were not included together in the same pooled estimates. Random-effects models estimated risk ratios (RRs) and mean differences (MDs) with 95% confidence intervals (CIs). Results Six retrospective cohort studies involving patients undergoing lumbar fusion were included. Gabapentinoid exposure was not significantly associated with persistent opioid use or prescription at the longest compatible follow-up (RR, 1.03; 95% CI, 0.89–1.19; P = 0.67) or at 3–6 months (RR, 1.03; 95% CI, 0.81–1.32; P = 0.73). There were also no significant differences in inpatient opioid consumption (MD, 43.13 morphine milligram equivalents; 95% CI, −9.72 to 95.99; P = 0.07) or change in the Oswestry Disability Index at 12 months (MD, 2.73 points; 95% CI, −8.54 to 14.00; P = 0.41). Findings for persistent opioid use were consistent in temporal and publication-level sensitivity analyses. Conclusions Observational evidence showed no statistically significant association between gabapentinoid exposure and persistent opioid use or prescription after lumbar fusion. There were also no significant differences in inpatient opioid consumption or 12-month changes in back pain, leg pain, or disability scores. Clinical Relevance Gabapentinoid use should remain individualized; these findings do not establish a benefit in reducing long-term opioid use after lumbar fusion. Level of Evidence 3. Registration PROSPERO CRD420261493895.
No takes yet. Share an insight, caveat, or question.
Alves et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: